Immortal Dragons Invests in Etheros Pharmaceuticals' Catalytic Antioxidant Platform for Age-Related Diseases
核心洞察
Immortal Dragons (搜索), a $40 million longevity fund, has made a strategic investment in Etheros Pharmaceuticals (搜索), which is developing water-soluble fullerene derivatives as catalytic antioxidants to combat aging-related diseases.
Etheros' lead compound demonstrated a 14% median lifespan extension in middle-aged mice and showed normalizing effects on behavior and neuroinflammation in an Alzheimer's disease mouse model.
The company's fullerene-based platform targets oxidative stress through catalytic dismutation, with a single molecule capable of neutralizing thousands of reactive oxygen species per second.
Immortal Dragons (搜索), a Singapore-based $40 million longevity fund, has announced a strategic investment in Etheros Pharmaceuticals (搜索), a Nashville-based biotechnology company developing a novel class of catalytic antioxidants targeting age-related diseases. The investment supports Etheros' advancement of water-soluble fullerene derivatives designed to neutralize oxidative stress, a fundamental mechanism implicated in cellular damage and aging.
Novel Catalytic Antioxidant Platform
Etheros' platform builds on fullerene chemistry, originating from the 1985 discovery of the C60 carbon sphere, which was recognized with the 1996 Nobel Prize in Chemistry. While naturally occurring C60 is insoluble in water, Etheros has developed proprietary water-soluble derivatives for therapeutic applications. These compounds possess chemistry that enables them to mimic the body's endogenous antioxidant enzymes, particularly superoxide dismutase.
Unlike conventional antioxidants that are consumed during the neutralization of reactive oxygen species, Etheros' fullerene derivatives are catalytic. A single molecule can neutralize thousands of reactive oxygen species molecules per second through catalytic dismutation. The company's lead compound has demonstrated a catalytic rate for superoxide removal within the range of other superoxide dismutase mimetics currently under investigation.
Promising Preclinical Results
The underlying science has shown promising results across diverse disease models. In one study involving wild-type mice, median lifespan increased by 14% when treatment began in middle age, comparable to the lifespan extension observed with caloric restriction in the same experiment. Additional studies showed that elderly mice treated with the compound outperformed untreated controls in tests of learning and memory.
Early work demonstrated neuroprotective effects in models of familial ALS and Parkinson's disease. Following toxicology studies that established a wide safety margin, new data showed normalizing effects on behavior and neuroinflammation in a mouse model of Alzheimer's disease.
Strategic Investment Focus
The investment aligns with Immortal Dragons (搜索)' strategy of targeting fundamental mechanisms of aging. By addressing oxidative damage, Etheros is focusing on a biological process associated with multiple chronic conditions, including neurodegenerative and cardiovascular diseases.
"Etheros represents an investment in a differentiated platform addressing oxidative stress through catalytic antioxidants," said Boyang Wang, founder of Immortal Dragons (搜索). "Their approach to this fundamental aspect of aging biology complements our portfolio strategy and contributes to our mission in the longevity space."
Dr. Jack Scannell, Chief Executive Officer of Etheros, commented: "Immortal Dragons (搜索) are both bold and thoughtful. That is a difficult mix to get right. And from a practical perspective, they have also been great to work with; really supportive."
Development Strategy and Next Steps
Etheros will use the new funding to advance its lead compound toward human clinical trials. The company's development strategy focuses on establishing early proof-of-concept in indications with defined biomarkers and clear clinical endpoints, while building a broader long-term platform targeting major age-related diseases.
Key upcoming milestones include completing the regulatory studies required for an Investigational New Drug filing, scaling up GMP manufacturing of the lead candidate, and developing biomarkers to measure drug activity in both preclinical models and future human trials. These steps provide multiple pathways for demonstrating the potential impact of the company's catalytic antioxidant platform.
The investment marks a significant step forward in advancing Etheros Pharmaceuticals (搜索)' fullerene-derived therapeutic program. By targeting oxidative stress, a fundamental driver of aging and associated diseases, Etheros aims to build a versatile platform capable of addressing multiple chronic conditions as it moves toward first-in-human studies.